Pomalyst indication?

What indications does Pomalyst (pomalidomide) have?

Pomalyst (pomalidomide) is an immunomodulatory drug used for specific blood cancers. The label indications focus on multiple myeloma in particular settings (including patients who have had prior therapy).

Which Pomalyst indication applies to relapsed or refractory multiple myeloma?

Pomalyst is used in relapsed or refractory multiple myeloma, typically after patients have already received other treatments. It is commonly referenced for use after prior line(s) of therapy when the disease has returned or does not respond to treatment.

What combination is Pomalyst used with for its myeloma indication?

In practice, Pomalyst is most often discussed as part of a combination regimen in multiple myeloma (for example, with dexamethasone) depending on the specific labeled regimen.

What patients usually ask next: who qualifies for Pomalyst?

Patients and clinicians usually look for the labeled scenario: confirmed multiple myeloma plus prior treatment history that matches the indication. Eligibility is also affected by factors such as prior exposure to key agents and the specific regimen described in the prescribing information.

Patent/exclusivity lookups (if you’re researching access or competition)

If you’re checking competitive products, patent status, or exclusivity for pomalidomide, DrugPatentWatch.com is a useful starting point: DrugPatentWatch.com

Sources

1. DrugPatentWatch.com